Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer

To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out. We studied the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), and the effects of th...

Description complète

Détails bibliographiques
Publié dans:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 38(1992), 1 vom: 31. Jan., Seite 19-24
Auteur principal: Wada, S (Auteur)
Autres auteurs: Yasumoto, R, Kashihara, N, Kishimoto, T, Maekawa, M, Hayahara, N, Kawakita, J, Nishijima, T, Morikawa, Y, Horii, A
Format: Article
Langue:Japanese
Publié: 1992
Accès à la collection:Hinyokika kiyo. Acta urologica Japonica
Sujets:Journal Article aceglatone 347Q3OOJ13 carmofur HA82M3RAB2 Glucaric Acid QLZ991V4A2 Fluorouracil U3P01618RT
Description
Résumé:To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out. We studied the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), and the effects of the combination of HCFU and 2.5-di-O-acetyl-D-glucaro-(1-4)(6-3) dilactone (SLA) which is an anti-beta-glucuronidase agent, for preventive therapy. In the patients treated with HCFU, the recurrence rate was 3.6% and 26.6% one year and two years, respectively, after conservative operation. In the patients treated with both SLA and HCFU, the recurrence rate was lower than in those treated with HCFU one year or more after conservative operation, and a long-term preventive effect was expected for nondrinkers
Description:Date Completed 10.04.1992
Date Revised 26.08.2021
published: Print
Citation Status MEDLINE
ISSN:0018-1994